% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

  • kmaggon kmaggon Mar 2, 2011 2:42 AM Flag

    Danoprevir vs Telaprevir

    With the likely approval of telaprevir (VRTX) and boceprevir (MRK) by the FDA and EMA in the 2Q2011, Roche dominance of the HCV market with Pegasys may end in the next few years. Roche Danoprevir protease inhibitors for is few years behind and may not have any perceived advantages. The next hepatitis C market war is going to be between telaprevir, boceprevir and danoprevir with projected peak sales of $ 5 billion each. The lofty $ 9 billion market cap of Vertex is riding on the perception of telaprevir market dominance and leadership. The current HCV market is worth $ 3 billion. With Roche Pegasys as the leading brand by sales. First multimedia review of the 3 protease inhibitors and strategy of Vertex, Merck and Roche to introduce costly new treatment
    Boceprevir (Merck) & Telapravir (Vertex) Hepatitis C Review

28.62-0.32(-1.11%)Oct 25 3:59 PMEDT